GlassScriptPhysician profile
Mansoor Javeed
NPI 1205802907
$16,773.39
in general payments reported to CMS, 2019-2025
72 companies · $1,963 in 2025
The $1,963 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,310 · 2020: $1,493 · 2021: $2,377 · 2022: $2,136 · 2023: $2,896 · 2024: $2,598 · 2025: $1,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,017 · Education: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,016.71 |
| Education | $1,440.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,740.79 | 2019-2025 | Erleada, Rybrevant, Talvey |
| Genentech USA, INC. | $1,020.35 | 2019-2025 | Venclexta, Polivy, Perjeta |
| Astellas Pharma US INC | $962.80 | 2019-2025 | Padcev, Xtandi |
| Astrazeneca Pharmaceuticals LP | $936.49 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Seagen INC. | $920.53 | 2020-2025 | Adcetris, Padcev |
| Pfizer INC. | $888.08 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $703.51 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $674.62 | 2019-2025 | Kisqali |
| Amgen INC. | $617.89 | 2019-2023 | Lumakras, Vectibix, Nplate |
| Incyte Corporation | $454.26 | 2020-2024 | Monjuvi, Pemazyre, Jakafi |
| Sanofi-Aventis U.S. LLC | $443.36 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $374.52 | 2019-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $374.05 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Abbvie INC. | $335.14 | 2019-2025 | |
| Genzyme Corporation | $309.87 | 2020-2025 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansoor Javeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.